A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation
JA Jakubowski, C Zhou, S Jurcevic, KJ Winters… - Thrombosis …, 2014 - Elsevier
Abstract Introduction Prasugrel, a P2Y 12 adenosine diphosphate (ADP) receptor antagonist
effectively inhibits ADP-mediated platelet activation and aggregation, and may be useful in
reducing vaso-occlusive crises in sickle cell disease (SCD). In this study, we assess the
effect of prasugrel on biomarkers of platelet activation and coagulation in patients with SCD.
Materials and Methods Twelve adult patients with SCD and 13 healthy subjects were
examined before and after 12±2 days of 5.0 or 7.5 mg/day oral prasugrel. Assessed cellular …
effectively inhibits ADP-mediated platelet activation and aggregation, and may be useful in
reducing vaso-occlusive crises in sickle cell disease (SCD). In this study, we assess the
effect of prasugrel on biomarkers of platelet activation and coagulation in patients with SCD.
Materials and Methods Twelve adult patients with SCD and 13 healthy subjects were
examined before and after 12±2 days of 5.0 or 7.5 mg/day oral prasugrel. Assessed cellular …
